ARVO 2025: Editorial Board Members set to present data

(Image credit: AdobeStock/Legacy Images)

The 2025 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting will take place May 4-8, 2025, in Salt Lake City, Utah. This meeting will feature presenter and researcher from around the globe as they share innovations in eye care, new technologies, and data from clinical trials.

As the presenters prepare for their poster sessions and podium speeches, we are highlighting some of the scheduled sessions that will feature members of the Editorial Advisory Board of Ophthalmology Time, Modern Retina, and Ophthalmology Times Europe.

Charles Wykoff, MD, PhD

• Poster B0048: Safety, tolerability, and properties of novel C3 inhibitor BI-C in patients with GA
• Sunday, May 4, 2025, 1:00-2:45 PM MT

Rishi P. Singh, MD

• Poster: B0088: Two-year real-world clinical outcomes in patients with diabetic macular edema treated with faricimab in the US: The FARETINA-DME study
• Monday, May 5, 2025. 3:00-4:45 PM MT
• Summary: The FARETINA-DME study evaluates real-world effectiveness, safety, and durability of faricimab for DME treatment. Results show improved vision and reduced swelling in patients with DME treated with faricimab.

Anat Loewenstein, MD

• Poster B0300: Interim results of the DME AWARE Delphi Study on unmet needs in DME patient management
• Monday, May 5, 2025, 3:00-4:45 PM MT
• Summary: DME AWARE Delphi Study identifies unmet needs in DME patient management. Experts reached consensus on early intervention definitions, treatment considerations, and switch criteria. Novel therapies and mechanisms are needed to address disease progression.

Judy E. Kim, MD, FARVO, FASRS

• Presentation: Lower socioeconomic status is associated with increased bevacizumab use among patients initiating anti-vascular endothelial growth factor (anti-VEGF) therapy for diabetic macular edema (DME)
• Wednesday, May 7, 2025, 11:45 AM -12:00 PM MT
• Summary: Lower socioeconomic status is linked to increased use of bevacizumab among patients with diabetic macular edema.

Prof Jean-François Korobelnik

• Presentation: A PULSAR phase 3 trial post-hoc analysis: Evaluating the timing and magnitude of control of disease activity with aflibercept 8 mg and faricimab, applying similar disease activity criteria across different pivotal Phase 3 trials for nAMD
• Sunday, May 4, 2025, 1:15-1:30 PM MT

Tunde Peto, MD, PhD, FRCOphth

• Poster: B0075: Effectiveness and safety of faricimab in eyes with DME in the United Kingdom: 1-year results from the FARWIDE-DME study
• Monday, May 5, 2025, 3:00-4:45 PM MT

Quan Dong Nguyen, MD, MSc, FARVO, FASRS

• Poster A0412: Association of ocular inflammation with anti-adalimumab antibodies in the management of autoimmune diseases
• May 4, 202,5 Sunday, 8:00-9:45 AM MT
• Summary: Anti-adalimumab antibodies associated with ocular inflammation in autoimmune disease management.

David A. Eichenbaum, MD FASRS

• Poster: A0382: Real-world treatment patterns in patients with macular edema (ME) due to noninfectious uveitis (NIU) in the United States
• May 4, 2025 1:00-2:45 PM MT
• Summary: Real-world treatment patterns in US patients with macular edema due to noninfectious uveitis were analyzed using a large database. Locally administered corticosteroids remain the standard of care but are associated with side effects. An unmet need exists for effective and safe nonsteroid alternatives.

Robert N. Weinreb, MD

• Minisymposium: Revisiting Clinical Trial Endpoints in Glaucoma
• Tuesday, May 6, 2025, 4:40-4:54 PM MT
• Summary: Glaucoma clinical trial endpoints revisited, with focus on visual field and structural parameters as surrogates for neuroprotection.

Stay tuned to Modern Retina for our coverage of the 2025 ARVO annual meeting.